Cat.No. : CSC-RO0032 Host Cell: BXPC-3
Size: >1x10^6 cells/vial Validation: T7 Endonuclease I assay
| Cat. No. | CSC-RO0032 |
| Description | BXPC-3-Cas9 cell line is engineered to stably overexpress Cas9 nuclease. The Cas9 nuclease in BXPC-3-Cas9 cell line has been functionally validated using T7 Endonuclease I assay. In combination with separately transfected sgRNAs, BXPC-3-Cas9 cell line can be used to efficiently generate targeted genomic modifications including gene knockout, gene knockin, gene mutagenesis, gene tagging etc. It is also an ideal cell line model for sgRNA screening and validation, either individually or in pools. |
| Introduction | Clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 is a gene-editing technology that contains two essential components: a guide RNA (gRNA) to match a target gene, and the Cas9 (CRISPR-associated protein 9) endonuclease which causes a double-stranded DNA break, allowing modifications to the genome via nonhomologous end joining (NHEJ) or homology-directed repair (HDR). |
| Target Gene | Cas9 |
| Host Cell | BXPC-3 |
| Host Cell Species | Homo sapiens (Human) |
| Product Type | Cas9 overexpression stable cell line |
| Applications | 1) CRISPR genome editing, such as gene knockout (KO), gene knockin (KI), gene mutagenesis, gene tagging etc. 2) High-throughput sgRNA screening and validation |
| Quality Control | 1) T7E1 assay 2) Mycoplasma detection |
| Size Form | One vial of frozen cells, typically >1x10^6 cells/vial |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
TGF-β signaling is essential in pancreatic ductal adenocarcinoma (PDAC) development, altered in all PDAC cases as one of four major pathways. Researchers demonstrate the crucial role of SMAD2/3 in pancreatic ductal adenocarcinoma (PDAC) progression, particularly in SMAD4-null contexts. By investigating TGF-β signaling in PDAC cells lacking SMAD4, they reveal SMAD2/3's oncogenic effects, influencing collective migration through FAK and Rho/Rac signaling pathways. RNA-sequencing analyses unveil a TGF-β gene signature linked to aggressive behavior, facilitated by SMAD2/3 activation. Additionally, clinical data suggests that SMAD4-negative tumors with elevated phospho-SMAD2 levels exhibit increased aggressiveness and poorer prognosis. These findings underscore the complex interplay between TGF-β signaling components in PDAC, highlighting SMAD2/3 as potential therapeutic targets.
Figure 1. A double SMAD2/SMAD3 knockout BxPC-3 (SMAD4-negative) pancreatic cancer cell line was generated. SMAD protein expression and localization in response to TGF-β treatment were assessed. Altered SMAD2/3 levels and distribution were observed in knockout cells compared to controls, providing insights into TGF-β signaling in pancreatic cancer progression. (Bertrand-Chapel A, et al., 2022)
Utilizing Creative Biogene's Cas9 Stable Cell Line-BXPC-3 streamlines the process of SMAD2/SMAD3 gene knockout experiments. This stable cell line is directly amenable to CRISPR/Cas9 gene editing technology, facilitating the rapid generation of SMAD2/SMAD3 knockout cell lines, thereby saving time and resources. Such cell lines can be instrumental in investigating the TGF-β signaling pathway and its implications in pancreatic cancer progression, enhancing the convenience and efficiency of related disease research endeavors.
A: THP-1 cells were likely selected for their monocytic lineage and expression of CD19, making them suitable for evaluating the functionality of the Anti-hCD19-CAR(3G) construct in targeting CD19-positive cells.
A: Stability and expression were likely assessed through flow cytometry, immunoblotting, or functional assays measuring CAR-mediated cytotoxicity or cytokine release, with appropriate selection pressure applied.
A: Characterization may involve analysis of CAR expression levels, binding affinity to CD19, activation-induced signaling pathways, and functional implications in antigen-specific killing of CD19-positive cells.
A: Quality control likely included confirmation of CAR expression and functionality, assessment of off-target effects, and validation of phenotypic changes associated with CAR activation.
A: Comparative analysis with primary T cells or in vivo models helps validate the efficacy and safety of Anti-hCD19-CAR(3G) therapy, guiding its development as a promising treatment for B cell malignancies such as leukemia and lymphoma.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Remarkable reliability! The Cas9 Stable Cell Line in BXPC-3 cells has been indispensable in our genome editing studies. Its stable expression of Cas9 has facilitated precise and efficient gene modifications, enabling us to dissect the functional significance of specific genetic alterations in cancer.
Trustworthy and effective! The stable expression of Cas9 in BXPC-3 cells has allowed us to perform targeted genome editing with high accuracy and fidelity. Its consistent Cas9 expression has ensured reliable and reproducible results, enhancing the reliability of our experiments.
Streamlining our research! With the Cas9 Stable Cell Line, we've been able to investigate the role of specific genes in cancer development and progression with confidence. Its stable expression of Cas9 has streamlined experimental workflows and accelerated the pace of our research.
Impressive performance! The Cas9 Stable Cell Line has consistently exhibited efficient Cas9-mediated genome editing, exceeding our expectations. Its stable expression has been instrumental in unraveling the genetic determinants of cancer phenotypes and identifying potential therapeutic targets.
A valuable tool in cancer genomics! The Cas9 Stable Cell Line has transformed our understanding of cancer biology. Its stable expression of Cas9 has provided a versatile platform for exploring gene function and dissecting molecular mechanisms underlying tumorigenesis.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
